期刊文献+

白念珠菌耐药机制新进展 被引量:7

New progress on the drug resistance mechanisms of Candida albicans
下载PDF
导出
摘要 近年来对于深部真菌感染的研究报道越来越多,其已日益成为一些重要疾病临床治疗过程中的常见并发症,其中,白念珠菌病的发病率仍居高不下。虽然目前有多种抗真菌药物应用于临床,但其耐药现象愈来愈严重,给临床治疗带来了极大的挑战。近来有关白念珠菌耐药机制的研究有了较新的进展。该文就新发现的白念珠菌的耐药机制,作一概述。 In recent years,more and more research about deep fungal infections has been reported,it has increasingly become the common complications during the clinical treatment of several important diseases,among which,the incidence of candidiasis remains unacceptably high.Although there are many kinds of antifungal drugs used in clinic,the drug resistance is becoming more and more serious,which has brought great challenge to the clinical treatment.Recent studies on the mechanism of drug resistance of Candida albicans showed new progress.In this article,the new mechanisms of drug resistance about C.albicans are reviewed briefly.
出处 《中国真菌学杂志》 CSCD 2013年第5期311-315,共5页 Chinese Journal of Mycology
基金 国家自然科学基金(81271798) 国家973项目(2013CB531602)
关键词 白念珠菌 耐药机制 进展 Candida albicans drug resistance mechanisms progress
  • 相关文献

参考文献30

  • 1AkinsR A. An update on antifungal targets and mechanisms of resistance in Candida albicans[J].Medical Mycology,2005,(04):285-318.doi:10.1080/13693780500138971.
  • 2Morschhauser J. The genetic basis of fluconazole resistance development in Candida albicans[J].Biochimica Et Biophysica Acta,2002,(2-3):240-248.
  • 3Guinea J,Sanchez-Somolinos M,Cuevas O. Fluconazole resistance mechanisms in Candida krusei:the contribution of efflux-pumps[J].Medical Mycology,2006,(06):575-578.doi:10.1080/13693780600561544.
  • 4Mansfield BE,Oltean HN,Oliver BG. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi[J].PLoS Pathogens,2010,(09):e1001126.
  • 5Chau AS,Gurnani M,Hawkinson R. Inactivation of sterol △5,6-desaturase attenuates virulence in Candida albicans[J].Antimicrobial Agents and Chemotherapy,2005,(09):3646-3651.doi:10.1128/AAC.49.9.3646-3651.2005.
  • 6Coste A,Turuer V,lscher F. A mutationin Taclp,a transcription factor regulating CDR 1 and CDR 2,is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans[J].Genetics,2006,(04):2139-2156.doi:10.1534/genetics.105.054767.
  • 7Dunkel N,Blass J,Rogers PD,Morschh(a)user J. Mutations in the multidrug resistance regulator MRR 1,followed by loss of heterozygosity,are the main cause of MDR 1 overexpression in fluconazole-resistant Candida albicans strains[J].Molecular Microbiology,2008,(04):827-840.doi:10.1111/j.1365-2958.2008.06309.x.
  • 8Dunkel N,Liu TT,Barker KS. A Gain-of-Function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate[J].Eukaryotic Cell,2008,(07):1180-1190.doi:10.1128/EC.00103-08.
  • 9Znaidi S,Barker KS,Weber S. Identification of the Candida albicans Cap1 p Regulon[J].Eukaryotic Cell,2009,(06):806-820.
  • 10Schubert S,Barker KS,Znaidi S. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1,Upc2,and Cap1 in Candida albicans[J].Antimicrobial Agents and Chemotherapy,2011,(05):2212-2223.

同被引文献62

引证文献7

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部